×

Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion

By Thomson Reuters Nov 16, 2026 | 3:10 PM

Nov 16 (Reuters) – Drugmaker Eli Lilly has signed an oncology ​research collaboration and ‌licensing agreement worth up to $5.9 billion with Stipple Bio, the privately ‌held ​biotech ⁠firm said on ⁠Monday.

Stipple Bio said it will identify cancer-specific molecules using its ​Pointillist discovery platform, while Lilly will ⁠use those ⁠to develop cancer ​therapies.

Stipple Bio will receive ​an upfront payment, an ‌equity investment from Lilly, and aggregate payment up to $5.9 ⁠billion in research, development and commercial milestone payments, as ⁠well ‌as tiered ⁠royalties on product ​sales ‌if any therapies ​resulting ⁠from the collaboration reach the market.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal ​Muhammed)